Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 263

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection

Open access
Ng, Enders K. O., Li, Rufina, Shin, Vivian Y., Jin, Hong Chuan, Leung, Candy P. H., Ma, Edmond S. K., Pang, Roberta, Chua, Daniel, Chu, Kent-Man, Law, W. L., Law, Simon Y. K., Poon, Ronnie T. P., Kwong, Ava·2013·PLoS ONE

Abstract

BACKGROUND: We previously showed microRNAs (miRNAs) in plasma are potential biomarkers for colorectal cancer detection. Here, we aimed to develop specific blood-based miRNA assay for breast cancer detection. METHODOLOGY/PRINCIPAL FINDINGS: TaqMan-based miRNA profiling was performed in tumor, adjacent non-tumor, corresponding plasma from breast cancer patients, and plasma from matched healthy controls. All putative markers identified were verified in a training set of breast cancer patients. Selected markers were validated in a case-control cohort of 170 breast cancer patients, 100 controls, and 95 other types of cancers and then blindly validated in an independent set of 70 breast cancer patients and 50 healthy controls. Profiling results showed 8 miRNAs were concordantly up-regulated and 1 miRNA was concordantly down-regulated in both plasma and tumor tissue of breast cancer patients. Of the 8 up-regulated miRNAs, only 3 were significantly elevated (p<0.0001) before surgery and reduced after surgery in the training set. Results from the validation cohort showed that a combination of miR-145 and miR-451 was the best biomarker (p<0.0001) in discriminating breast cancer from healthy controls and all other types of cancers. In the blind validation, these plasma markers yielded Receiver Operating Characteristic (ROC) curve area of 0.931. The positive predictive value was 88% and the negative predictive value was 92%. Altered levels of these miRNAs in plasma have been detected not only in advanced stages but also early stages of tumors. The positive predictive value for ductal carcinoma in situ (DCIS) cases was 96%. CONCLUSIONS: These results suggested that these circulating miRNAs could be a potential specific biomarker for breast cancer screening.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0053141

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 263

Metadata

Authors
Ng, E. K. O., Li, R., Shin, V. Y., Jin, H. C., Leung, C. P. H., Ma, E. S. K., Pang, R., Chua, D., Chu, K.-M., Law, W. L., Law, S. Y. K., Poon, R. T. P., & Kwong, A.
Venue
PLoS ONE
Published
2013-01-03
Volume
8
Issue
1
Pages
e53141
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2169583213
Cited by
263
References
37
FWCI
12.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection. https://app.cochat.ai/papers/10.1371/journal.pone.0053141
The paper
Ng, E. K. O., Li, R., Shin, V. Y., Jin, H. C., Leung, C. P. H., Ma, E. S. K., Pang, R., Chua, D., Chu, K.-M., Law, W. L., Law, S. Y. K., Poon, R. T. P., & Kwong, A. (2013). Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection. PLoS ONE. https://doi.org/10.1371/journal.pone.0053141

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.